LINC02517: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Target Name: LINC02517

NCBI ID: G105374374

LINC02517

Other Name(s): Long intergenic non-protein coding RNA 2517, transcript variant 1 | long intergenic non-protein coding RNA 2517

LINC02517: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Introduction

LINC02517 is a long non-protein-coding RNA (lncRNA) molecule, located on chromosome 6p12, has been identified as a potential drug target and biomarker. It is characterized by its unique structure, length, and expression patterns. LINC02517 is a non- coding RNA molecule that is transcribed from the intergenic region between exons 2 and 3 of the APC gene. It is different from other lncRNAs in that it has a higher stability and a longer half-life, suggesting a role in regulating gene expression.

Structure and Expression

The structure of LINC02517 is unique among known lncRNAs. It is a 231-nt RNA molecule with a stem-loop structure and a 3'-end that is terminated by a uracil(U) tract. The stem-loop region is composed of three loops, each of which is composed of three alternating AUG/GUAU and U/AUG base pairs. The loops are connected by a single U tract that spans the length of the molecule. The 3'-end of the LINC02517 is a GCAATTTG sequence , which is a repeat of the ATCGATTTG sequence that is also present in the 3'-end of the APC gene.

Expression of LINC02517

LINC02517 is highly expressed in various tissues and organs, including brain, heart, muscle, liver, and pancreas. It is also expressed in the placenta and testes, but its expression is significantly higher in the brain. LINC02517 is also expressed in the bloodstream, which suggests that it may have a role in the immune system.

Drug Target Potential

The unique structure and expression patterns of LINC02517 make it an attractive drug target. Its stem-loop structure and the multiple AUG/GUAU and U/AUG base pairs in the stem-loop region suggest that it may play a role in regulating protein synthesis and may be a target for small molecules that can modulate stem-loop activity. Additionally, its expression in the brain suggests that it may be involved in the regulation of neuronal function and behavior.

Biomarker Potential

The unique expression patterns of LINC02517 make it a potential biomarker for various diseases. For example, high expression of LINC02517 has been associated with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, LINC02517 has also been shown to be involved in the regulation of inflammation, which suggests that it may be a potential target for anti-inflammatory drugs.

Conclusion

LINC02517 is a unique and highly expressed lncRNA molecule that has a potential role in the regulation of gene expression and protein synthesis. Its stem-loop structure and long half-life suggest that it may be a potential drug target. Furthermore, its expression patterns in various tissues and its potential involvement in the regulation of neuronal function and behavior make it a promising biomarker for various diseases. Further research is needed to fully understand the role of LINC02517 in the regulation of gene expression and protein synthesis, as well as its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2517

The "LINC02517 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02517 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets